Igmesine

Igmesine (also known as JO 1784 or HOE 1784) is a serotonin reuptake inhibitor that was developed by Hoechst AG in the 1980s for the treatment of depression. However, it was never marketed.

Pharmacology

Igmesine acts as a potent and selective serotonin reuptake inhibitor (SRI), with a high affinity for the serotonin transporter (SERT). It has low affinity for other neurotransmitter transporters and receptors and hence lacks significant norepinephrine reuptake inhibitor (NRI) or dopamine reuptake inhibitor (DRI) action.

History

Igmesine was developed by Hoechst AG in the 1980s. It reached phase III clinical trials for the treatment of depression, but was not marketed.

See also

• List of investigational antidepressants

Igmesine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski